Robin Gasiorowski

Dr. Robin Gasiorowski is a Clinical Professor of Haematology at Macquarie University, with appointments at Concord and Macquarie University Hospitals. He specializes in clinical and laboratory haematology, focusing on acute leukaemia, high-grade lymphoma, and novel immune therapies. His research includes developing therapeutic antibodies for Acute Myeloid Leukaemia (AML), contributing to clinical trials for lymphoma and leukaemia treatments. He holds a PhD from the University of Sydney’s Dendritic Cell Research Group and has led industry and Australasian Leukaemia and Lymphoma Group (ALLG) sponsored trials. His work emphasizes translational research, bridging basic science and clinical application.

• Education: MBBS from Cambridge University and University College London.
• Research Interests: Immune therapies, bispecific antibodies (e.g., epcoritamab), and genomic approaches in lymphoma/leukaemia. He also investigates environmental health impacts, such as PFAS levels in firefighters.

Publications span high-impact journals like Leukemia, Journal of Clinical Oncology, and Blood, reflecting his expertise in clinical trials and translational oncology. He collaborates widely, including with the Australasian Lymphoma Alliance and international research teams.

His clinical practice integrates advanced therapies, with a focus on improving outcomes for patients with relapsed/refractory haematological malignancies. He advocates for standardized protocols in haematological malignancy management, particularly during pandemics like COVID-19.